Centrient Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 170.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 160.30 Cr
as on 16-11-2024
- Company Age 31 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 200.00 Cr
as on 16-11-2024
- Revenue 13.46%
(FY 2023)
- Profit -31.41%
(FY 2023)
- Ebitda -9.72%
(FY 2023)
- Net Worth 8.75%
(FY 2023)
- Total Assets 2.79%
(FY 2023)
About Centrient Pharmaceuticals India
The Corporate was formerly known as Dsm Anti Infectives India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 170.00 Cr and a paid-up capital of Rs 160.30 Cr.
The company currently has active open charges totaling ₹200.00 Cr.
The Key Managerial Personnel (KMP) at Centrient Pharmaceuticals India Private Limited India are Sumit Agarwal as COMPANY SECRETARY and Vikram Sehgal as Cfo. Namit Joshi, Vikram Sehgal, and Devesh Srivastava serve as directors at the Company.
- CIN/LLPIN
U24231PB1993PTC023090
- Company No.
023090
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 1993
- Date of AGM
12 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Nawanshahr, Punjab, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Centrient Pharmaceuticals India Private Limited offer?
Centrient Pharmaceuticals India Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Centrient Pharmaceuticals India?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sumit Agarwal | Company Secretary | 17-Dec-2020 | Current |
| Vikram Sehgal | CFO | 04-Jun-2021 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Sehgal  | Whole-Time Director | 30-Sep-2021 | Current |
| Namit Joshi | Whole-Time Director | 29-Jul-2021 | Current |
| Devesh Srivastava | Whole-Time Director | 01-Apr-2023 | Current |
Financial Performance and Corporate Structure Insights of Centrient Pharmaceuticals India.
Centrient Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.46% increase. The company also saw a substantial fall in profitability, with a 31.41% decrease in profit. The company's net worth moved up by a moderate rise of 8.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Centrient Pharmaceuticals India?
In 2023, Centrient Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmaceuticals Export Promotion Council Of IndiaActive 20 years 8 monthsNamit Joshi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Oct 2018 | ₹200.00 Cr | Open |
How Many Employees Work at Centrient Pharmaceuticals India?
Centrient Pharmaceuticals India has a workforce of 613 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Centrient Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Centrient Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
